C07H 19/056
Triazole or tetrazole radicals
C07H19/056 (Triazole or tetrazole radicals) appears on 174 US grants and 202 published applications in this corpus.
Search patents in C07H- Granted patents
- 174
- Published applications
- 202
- Assignees
- 114
- Inventors
- 443
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 3 | 0 |
| 1991 | 7 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 4 | 0 |
| 1999 | 1 | 0 |
| 2000 | 4 | 0 |
| 2001 | 3 | 0 |
| 2002 | 4 | 5 |
| 2003 | 5 | 6 |
| 2004 | 4 | 10 |
| 2005 | 3 | 8 |
| 2006 | 4 | 2 |
| 2007 | 3 | 10 |
| 2008 | 5 | 0 |
| 2009 | 4 | 6 |
| 2010 | 2 | 9 |
| 2011 | 1 | 6 |
| 2012 | 1 | 6 |
| 2013 | 3 | 5 |
| 2014 | 10 | 12 |
| 2015 | 5 | 8 |
| 2016 | 6 | 9 |
| 2017 | 6 | 7 |
| 2018 | 4 | 7 |
| 2019 | 8 | 11 |
| 2020 | 7 | 12 |
| 2021 | 9 | 17 |
| 2022 | 4 | 15 |
| 2023 | 11 | 11 |
| 2024 | 4 | 13 |
| 2025 | 13 | 6 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Amyloid targeting agents and methods of using the same22 Sep 2026US 12,741,949 B2Amydis, Inc.
- Galactoside inhibitor of galectins16 Dec 2025US 12,497,428 B2Galecto Biotech AB
- Galactoside inhibitor of galectins14 Oct 2025US 12,441,754 B2Galecto Biotech AB
- Galactoside inhibitor of galectins14 Oct 2025US 12,441,755 B2Galecto Biotech AB
- (2-acetamidyl)thio-beta-D-galactopyranoside derivatives9 Sep 2025US 12,410,208 B2Idorsia Pharmaceuticals Ltd
- Nucleoside line-1 inhibitors5 Feb 2026US 2026/0035403 A1Transposon Therapeutics, Inc.
- Multiplexing targeting ligands through click chemistry at the anomeric site of sugars12 Jun 2025US 2025/0188470 A1Alnylam Pharmaceuticals, Inc.
- Asgpr cell surface receptor binding compounds and conjugates27 Mar 2025US 2025/0101007 A1Lycia Therapeutics, Inc.
- Siglec ligands, conjugates, and methods of use thereof27 Feb 2025US 2025/0064941 A1
- Glycomimetic binders for l-sign27 Feb 2025US 2025/0066411 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Conformationally constrained L-nucleosides421US 6,525,191 B12003
- Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections149US 7,608,600 B2Centre National De La Recherche Scientifique · 2009
- Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes128US 5,767,097 AICN Pharmaceuticals, Inc. · 1998
- Nucleoside analogues119US 6,239,159 B1Amersham Pharmacia Biotech UK Limited · 2001
- Nucleoside compounds112US 6,495,677 B12002